2000
DOI: 10.1002/1521-3897(200006)342:6<537::aid-prac537>3.3.co;2-u
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
7
0

Year Published

2004
2004
2010
2010

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…Peptide macrocyclization, including peptide stapling, 2 has been shown to address these limitations and result in a molecule with increased potency. Cyclic peptides show increased stability to proteolytic degradation 3 relative to their linear precursors and are able to bind to their intended target at decreased effective concentrations, mainly attributed to the constrained conformation lowering the entropic cost of binding. 4 …”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Peptide macrocyclization, including peptide stapling, 2 has been shown to address these limitations and result in a molecule with increased potency. Cyclic peptides show increased stability to proteolytic degradation 3 relative to their linear precursors and are able to bind to their intended target at decreased effective concentrations, mainly attributed to the constrained conformation lowering the entropic cost of binding. 4 …”
mentioning
confidence: 99%
“…(ii) DMPA (1 equiv. ), hn (365 nm, 20 mW cm À2 ), 20-60 min; (iii) TFA/ TIPS/H 2 O. Alkenes were incorporated using Fmoc-Lys(Alloc)-OH monomer(1,3) or on-resin modification using 5-norbornene-2-carboxylic acid (2, 4).…”
mentioning
confidence: 99%
“…Some years later, Bass et al introduced disulfide-linked cyclic octapeptide antagonists which contained a DCys in position 6 and LCys in position 27 -Ac-(4-NO 2 -Phe)-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH 2 [189] 28 DC-38-48 Nal-c(DCys-Pal-DTrp-Lys-Val-Cys)-Nal-NH 2 [188] 29 PRL-2970 Cpa-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-Nal-NH 2 [190] 30 PRL-2915 Nal-c(DCys-Pal-DTrp-Lys-Tle-Cys)-Nal-NH 2 [190] 31 AC-178,335 Ac-DHis-DPhe-DIle-DArg-DTrp-DPhe-NH 2 [191] Abbrevation: Ahp, 7-aminoheptanoyl; Nal, 3-(2-naphthyl)alanine; Cpa, 4-chlorophenylalanine; Pal, 3-pyridylalanine; Tle, tert.-leucine; 11 relative to SRIF. One peptide (27) displayed high affinity binding to sst2 comparable to native somatostatin but reversed the somatostatin-mediated cAMP accumulation in rat somatomammotroph GH 4 C 1 cells as well as SRIFstimulated growth of sst2 expressing yeast cells. The antagonistic effect was assigned to the inverted chirality in position 6, since replacement by LCys led to the conversion into an agonist (Table 5) [189].…”
Section: Somatostatin Antagonistsmentioning
confidence: 99%
“…Since we found incomplete condensation of hydrophobic amino acids onto N α -functionalised building units we prefer the utilisation of preformed dipeptide building units. Both, the solution syntheses of suitable building units as well as the assembly of backbone cyclic peptide hormones on the solid phase were described by different authors and published in corresponding chemical journals [for a selection see [26][27][28].…”
Section: Conformational Restriction By Different Types Of Cyclizationmentioning
confidence: 99%
See 1 more Smart Citation